Subretinal Forcep Black Long
Navigation Links
Subretinal Forcep Black Long
| Products | Subretinal Forcep Black Long |
| Company | Bausch & Lomb Storz |
| Item | Subretinal Forcep Black Long |
| Features | |
| Description | Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip. |
| Info | Bausch & Lomb Storz Customer Service: (585) 338-6000 Web site: http://www.storz.com/ |
Related medicine products :
1. Subretinal Fluid Cannula - Curved
2. Subretinal Fluid Cannula - Straight
3. Thomas Subretinal Forceps
4. Thomas Subretinal Forceps - Black
5. Kaplan Subretinal Forceps
6. Thomas Long Subretinal Forceps
7. Subretinal Cannula
8. BD Visitec Subretinal Fluid Instruments
9. Subretinal Fluid Cannula
10. Subretinal Fluid Cannula Straight
11. Subretinal Fluid Cannula Curved
Breaking Medicine News(10 mins):Health News:Statement from American Water Works Association on the Environmental Working Group's report on Tap Water Quality Testing and Violations 2Health News:MDS Receives Notice of Application from PerkinElmer, Inc. 2Health News:MDS Receives Notice of Application from PerkinElmer, Inc. 3Health News:More 20 mph zones in London would prevent 100 killed or seriously injured casualties each year 2Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2
[0] Statement from American Water Works Association on the Environmental Working Group's report on Tap Water Quality Testing and Violations[0] MDS Receives Notice of Application from PerkinElmer, Inc.[0] Medicare Report Confirms Health Care Takeover Plan is a Fiscal Disaster[0] More 20 mph zones in London would prevent 100 killed or seriously injured casualties each year[0] Clinical trial advances new approach to re-sensitizing breast cancer
Other Medicine News:Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3
Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer ResearchPhysician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 PhysiciansStudy finds more effective treatment for pneumonia following influenzaAllscripts Reports Fiscal 2009 Second Quarter ResultsChindex International Inc. Announces Participation in the 2009 UBS Greater China ConferenceInflammation Markers May Help Predict Stroke Risk
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Fitness Might Limit Strokes Impact 51687 1Fitness Might Limit Strokes Impact 51687 2
[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer[0] Dynatronics Receives 180-Day NASDAQ Extension[0] Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |